SAGE Therapeutics (SAGE) Receiving Somewhat Positive News Coverage, Accern Reports
Headlines about SAGE Therapeutics (NASDAQ:SAGE) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SAGE Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.2379077169306 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern’s scoring:
- Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share (americanbankingnews.com)
- SAGE Therapeutics Inc (SAGE) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Technical data gathered from Sage Therapeutics, Inc. (SAGE) – Wall Street Morning (wallstreetmorning.com)
- SAGE Therapeutics (SAGE) vs. aTyr Pharma (LIFE) Financial Survey (americanbankingnews.com)
A number of equities analysts have recently commented on SAGE shares. Royal Bank of Canada lifted their target price on SAGE Therapeutics from $137.00 to $280.00 and gave the stock a “sell” rating in a report on Thursday, December 7th. They noted that the move was a valuation call. Chardan Capital upgraded SAGE Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $60.00 to $140.00 in a report on Friday, November 10th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $198.00 target price on shares of SAGE Therapeutics in a report on Friday, December 8th. Leerink Swann lifted their target price on SAGE Therapeutics from $123.00 to $246.00 in a report on Thursday, December 7th. Finally, Cowen reiterated a “buy” rating on shares of SAGE Therapeutics in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $171.21.
SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue was up .0% compared to the same quarter last year. research analysts anticipate that SAGE Therapeutics will post -7.42 EPS for the current year.
In related news, insider Albert Robichaud sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the sale, the insider now directly owns 152,759 shares of the company’s stock, valued at approximately $24,354,367.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stephen Kanes sold 44,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total value of $7,795,920.00. Following the sale, the insider now directly owns 46,348 shares of the company’s stock, valued at $8,211,938.64. The disclosure for this sale can be found here. Insiders have sold a total of 314,247 shares of company stock valued at $50,465,110 over the last three months. 6.10% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/sage-therapeutics-sage-receiving-somewhat-positive-news-coverage-accern-reports/1816149.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.